Lilly Drug Shows Survival Benefit In NSCLC, Raising Its Prospects
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Expectations for Eli Lilly’s ramucirumab were dampened after it failed in a Phase III trial in breast cancer patients, but enthusiasm for the drug has been reignited now that it demonstrated a survival benefit in one of oncology’s riskiest areas – lung cancer.
You may also be interested in...
Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial
Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.